fashion -WSS

fashion

author：Wikipedia 2025-09-27 07:51:48 - browse：56

a person wearing blue dress conducts a finger prick test on another person in a home setting — coverage from STAT — Adobe

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. Their products aren’t cheap, but in the long term, they pitch to health plans and employers that these digital tools will help cut health care costs by preventing serious complications like amputation and kidney failure.

A systematic review by the Peterson Health Technology Institute found, though, that digital tools used to manage diabetes with the help of finger-stick blood glucose readings don’t result in clinically meaningful improvements over standard care. As a result, they don’t reduce health care spending — they drive it up.

“Most of the solutions in this category do not deliver clinical benefits that justify their cost,” Caroline Pearson, executive director of the institute, told STAT. Despite finding that some populations may benefit, the report concludes that current evidence doesn’t support broader adoption for most products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Big Tobacco's 'harm reduction': Is it for real, or a sham?

focus

entertainment

WSS

Helping hospitals and community health centers plan for resilience

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Food makers tried to stack nutrition panel with preferred experts

Criminal prosecution for violating HIPAA: an emerging threat

Popular nasal decongestant doesn't actually relieve congestion

Pig kidney works a record two months in donated body

Wikipedia

fashion

knowledge

Moonlake's readout produced a cash windfall. Risks remain

What to make of Biden’s latest efforts on cancer research

Guidelines to prevent youth baseball injuries need more muscle

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How to make the FDA’s new prescription one

Drug repurposing or repositioning? The language matters

Cytokinetics CEO stresses company can launch heart drug on its own

Wildfire smoke exposes gaps in outdoor worker protections

Acelyrin, a rare IPO success, stumbles in its first big test

knowledge

Food makers to regulators: Ultra

FDA proposes changes to key medical devices approval pathway

How housing is health care on Long Island

Venture capitalist Bob Kocher on the state of digital health

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

focus

entertainment

hotspot

explore